Biota Pharmaceuticals Inc. (NASDAQ:AVIR)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Tuesday.

Separately, FBR & Co restated an “outperform” rating on shares of Biota Pharmaceuticals in a report on Tuesday, May 31st.

Biota Pharmaceuticals (NASDAQ:AVIR) traded up 6.62% on Tuesday, hitting $1.61. The stock had a trading volume of 59,819 shares. The company’s 50 day moving average is $1.37 and its 200 day moving average is $1.46. The firm’s market cap is $62.21 million. Biota Pharmaceuticals has a 12-month low of $1.23 and a 12-month high of $2.31.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/biota-pharmaceuticals-inc-avir-rating-reiterated-by-hc-wainwright.html

Biota Pharmaceuticals (NASDAQ:AVIR) last posted its quarterly earnings data on Wednesday, September 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by $0.43. Biota Pharmaceuticals had a negative return on equity of 46.02% and a negative net margin of 272.04%. On average, equities research analysts expect that Biota Pharmaceuticals will post ($0.89) EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of AVIR. Senzar Asset Management LLC purchased a new position in shares of Biota Pharmaceuticals during the second quarter worth $2,848,000. Vanguard Group Inc. purchased a new position in shares of Biota Pharmaceuticals during the second quarter worth $1,462,000. BlackRock Institutional Trust Company N.A. purchased a new position in shares of Biota Pharmaceuticals during the second quarter worth $691,000. FMR LLC purchased a new position in shares of Biota Pharmaceuticals during the second quarter worth $420,000. Finally, Stonepine Capital Management LLC purchased a new position in shares of Biota Pharmaceuticals during the second quarter worth $412,000. Hedge funds and other institutional investors own 34.53% of the company’s stock.

About Biota Pharmaceuticals

Aviragen Therapeutics, Inc, formerly Biota Pharmaceuticals Inc, is a biopharmaceutical company. The Company is focused on the discovery and development of direct-acting antivirals to treat infections. It has approximately four product candidates in clinical development that address viral infections that have limited therapeutic options.

5 Day Chart for NASDAQ:AVIR

Receive News & Ratings for Biota Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biota Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.